---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-114228"
form_type: "8-K"
ticker: "KMTS"
cik: "0001877184"
company_name: "KESTRA MEDICAL TECHNOLOGIES, LTD."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:54:25.159082+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kestra Medical Q1 FY26 revenue up 52% to $19.4M; raises FY26 guidance to $88M

## Summary
- Revenue $19.4M (+52% YoY); gross margin expanded to 45.7% from 32.9%.
- GAAP net loss $25.8M vs $20.3M; adjusted EBITDA loss $19.4M vs $15.7M.
- 4,205 prescriptions for ASSURE system, up 51% YoY; driven by new accounts and in-network mix.
- FY26 revenue guidance raised to $88M, representing 47% growth over FY25.
- Cash and equivalents $201.2M as of July 31, 2025.

## SEC filing metadata
- accession: 0000950170-25-114228
- form_type: 8-K
- ticker: KMTS
- cik: 0001877184
- company_name: KESTRA MEDICAL TECHNOLOGIES, LTD.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1877184/000095017025114228/0000950170-25-114228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1877184/000095017025114228/ck0001877184-20250911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-114228
- JSON: https://secwatch.observer/filing/0000950170-25-114228.json
- Plain text: https://secwatch.observer/filing/0000950170-25-114228.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.